Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. Keeping that in mind, here are three profitable companies to steer clear of and a few better alternatives.

AAON (AAON)

Trailing 12-Month GAAP Operating Margin: 10.1%

Backed by two million square feet of lab testing space, AAON (NASDAQ: AAON) makes heating, ventilation, and air conditioning equipment for different types of buildings.

Why Are We Cautious About AAON?

1. Efficiency has decreased over the last five years as its operating margin fell by 6 percentage points
2. Earnings per share fell by 22.7% annually over the last two years while its revenue grew, showing its incremental sales were much less profitable
3. Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 27.2 percentage points

AAON’s stock price of $101.64 implies a valuation ratio of 52.7x forward P/E. Read our free research report to see why you should think twice about including AAON in your portfolio.

Veralto (VLTO)

Trailing 12-Month GAAP Operating Margin: 23.2%

Spun off from Danaher in 2023, Veralto (NYSE: VLTO) provides water analytics and treatment solutions.

Why Does VLTO Fall Short?

1. Muted 4.1% annual revenue growth over the last four years shows its demand lagged behind its industrials peers
2. Anticipated sales growth of 6.3% for the next year implies demand will be shaky

At $92.01 per share, Veralto trades at 22.7x forward P/E. Dive into our free research report to see why there are better opportunities than VLTO.

Bio-Techne (TECH)

Trailing 12-Month GAAP Operating Margin: 9.6%

With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ: TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development.

Why Should You Dump TECH?

1. Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
2. Smaller revenue base of $1.22 billion means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
3. 11.6 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position

Bio-Techne is trading at $59.57 per share, or 30.7x forward P/E. Check out our free in-depth research report to learn more about why TECH doesn’t pass our bar.

High-Quality Stocks for All Market Conditions

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.